Lexicon Pharmaceuticals, Inc.
LXRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.45
KIRA · Stoqly’s AI analyst, in plain words
- Lexicon Pharmaceuticals, Inc. had $49.8M of revenue in fiscal 2025, up 60.2% on the year before. Over five years, revenue changed +15.7% a year on average.
- Its operating margin was −98.2%, up 536.0 pts: of every 100 in sales, about −98 is left after running the business.
- Lexicon Pharmaceuticals, Inc. lost $50.3M in fiscal 2025.
- Free cash flow was −$67.9M in fiscal 2025, −136.2% of revenue.
- Lexicon Pharmaceuticals, Inc. has $42.2M more cash than debt.
Market cap
$635M
P/E
—
Revenue
$49.8M
Net income
−$50.3M
Free cash flow
−$67.9M
Operating margin
−98.2%
Lexicon Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+60.2%
Yes. Sales grew 60.2% last year.
Does it make a profit?
−101.1%
No. It lost money last year.
Does profit turn into cash?
−136.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Lexicon Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- LEXICON PHARMACEUTICALS, INC.
- CIK
- 0001062822
Lexicon Pharmaceuticals, Inc. · LXRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.3M | $0.1M | $1.2M | $31.1M | $49.8M |
| Revenue growth | −98.8% | −53.4% | 766.2% | 2,481.5% | 60.2% |
| Gross margin | 100.0% | 100.0% | 92.9% | 98.0% | 99.4% |
| Operating margin | −29,224.8% | −72,489.2% | −14,265.0% | −634.2% | −98.2% |
| Net income | −$87.8M | −$102M | −$177M | −$200M | −$50.3M |
| Net margin | −29,449.0% | −73,341.0% | −14,710.9% | −644.8% | −101.1% |
| Diluted EPS | −$0.60 | −$0.62 | −$0.80 | −$0.63 | −$0.14 |
| Cash | |||||
| Cash from operations | −$87.0M | −$88.9M | −$162M | −$179M | −$67.9M |
| Capital expenditure | $1.2M | $1.3M | $0.5M | $1.0M | $0.0M |
| Free cash flow | −$88.2M | −$90.2M | −$162M | −$180M | −$67.9M |
| FCF margin | −29,610.1% | −64,875.5% | −13,485.6% | −578.5% | −136.2% |
| Share buybacks | $2.7M | $0.9M | $0.8M | $1.7M | — |
| Share count change | 31.4% | 13.8% | 33.4% | 44.7% | 13.4% |
| Debt and strength | |||||
| Cash and short-term investments | $86.7M | $138M | $170M | $238M | $96.2M |
| Debt incl. finance leases | $0.0M | $48.6M | $99.5M | $100M | $54.0M |
| Shareholders' equity | $114M | $117M | $93.1M | $146M | $108M |
| Current ratio | 4.0x | 6.1x | 5.6x | 5.4x | 4.9x |
| Interest coverage | −108.6x | −36.2x | — | — | — |
| Returns and quality | |||||
| Return on capital | −256.2% | −290.9% | −600.6% | −1,878.2% | −59.2% |
| Return on equity | −65.0% | −88.4% | −168.5% | −167.7% | −39.7% |
| Return on tangible equity | −127.1% | −140.5% | −364.7% | −197.6% | −79.9% |
| Piotroski F-score | 4 | 3 | 2 | 5 | 4 |
| Altman Z'' | −31.4 | −24.6 | −25.3 | −20.5 | −33.0 |
Insiders bought, 12 months
$2.7M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lexicon Pharmaceuticals, Inc. · LXRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.45 a share, the company is worth $635M.
Source: SEC EDGAR XBRL filings (CIK 0001062822). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.